GlassScriptPhysician profile
Angela Bonham
NPI 1689273773
$6,441.98
in general payments reported to CMS, 2019-2025
27 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,476 · 2022: $1,297 · 2023: $1,645 · 2024: $959 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,289 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,288.50 |
| Education | $380.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,193.34 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $960.67 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $811.94 | 2021-2025 | Ofev, Jascayd, Spiriva Respimat |
| Harmony Biosciences LLC | $803.81 | 2021-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $546.56 | 2021-2025 | |
| Genzyme Corporation | $424.15 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $252.72 | 2021-2025 | Glassia |
| Grifols USA, LLC | $227.85 | 2021-2025 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $171.86 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $156.64 | 2021-2025 | Opsumit, Uptravi |
| Electromed, INC. | $124.24 | 2022-2025 | Smartvest |
| Regeneron Healthcare Solutions, INC. | $121.57 | 2023-2025 | Dupixent |
| Abbvie INC. | $105.10 | 2021 | |
| Axsome Therapeutics, INC. | $94.96 | 2023-2024 | Sunosi |
| Amgen INC. | $74.91 | 2023-2025 | Tezspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $47.66 | 2023 | Hillrom - Life 2000 Ventilation System |
| Genentech USA, INC. | $42.91 | 2021-2023 | Xolair |
| Pulmonx Corporation | $40.94 | 2024-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Verona Pharma, INC. | $38.69 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $38.36 | 2023 | Inspire |
| Lilly USA, LLC | $37.67 | 2025 | Zepbound |
| Alexion Pharmaceuticals, INC. | $34.21 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $33.52 | 2021 | |
| Boston Scientific Corporation | $15.70 | 2021 | |
| Fisher & Paykel Healthcare INC | $15.04 | 2022 | |
| Merck Sharp & Dohme LLC | $13.82 | 2025 | Zerbaxa |
| Gilead Sciences, INC. | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Bonham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.